XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 2,346,978 $ 5,838,566
Investment in debt securities - available for sale, at fair value 7,461,875 9,857,087
Advances and deposits on clinical programs and other current assets 2,285,490 2,545,051
Total current assets 12,094,343 18,240,704
Property and equipment (at cost, less accumulated depreciation and amortization) 693,360 751,906
Other assets:    
Deferred income tax asset 1,280,385
Operating lease right-of-use assets, net 1,487,065 1,595,074
Deposits and other assets 50,000 50,000
Total other assets 1,537,065 2,925,459
Total assets 14,324,768 21,918,069
Current liabilities:    
Accounts payable – trade 2,357,776 3,515,192
Other accrued liabilities 1,958,575 3,390,521
Operating lease liability - current portion 500,625 485,421
Total current liabilities 4,816,976 7,391,134
Operating lease liability - non-current portion 1,008,049 1,139,293
Total liabilities 5,825,025 8,530,427
Commitments and contingencies
Stockholders’ equity:    
Preferred stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at March 31, 2024 and December 31, 2023)
Common stock - $0.01 par value (112,500,000 shares authorized; 9,400,911 and 9,399,811 shares issued at March 31, 2024 and December 31, 2023, respectively; and 9,400,889 and 9,399,789 shares outstanding at March 31, 2024 and December 31, 2023, respectively) 94,009 93,998
Additional paid-in capital 401,470,148 401,500,838
Accumulated other comprehensive loss 133,101 60,796
Accumulated deficit (393,112,327) (388,182,802)
Total stockholders’ equity before treasury stock 8,584,931 13,472,830
Treasury stock, at cost (22 shares at March 31, 2024 and December 31, 2023) (85,188) (85,188)
Total stockholders’ equity 8,499,743 13,387,642
Total liabilities and stockholders’ equity $ 14,324,768 $ 21,918,069